Health ❯ Healthcare ❯ Clinical Trials

Phase III Trials

ASPEN Trial Giredestrant Trials MATTERHORN Trial DESTINY-Breast05 Trial KOMET Trial Patient Outcomes Efficacy Studies Randomised Trials BRUIN CLL-321 COMBI-AD Study Weight Loss Efficacy CENTERSTONE Trial Orforglipron Chemotherapy Studies DESTINY-Breast09 Trial Immunological Response BREAKWATER Trial Dietary Interventions ENPP1 Deficiency Treatments DREAMM-7 Trial Atezolizumab HIMALAYA Trial Serena-6 Trial HD21 Trial EMBER-3 Trial ASPEN Study OLIGUITO Study Aceclidine Studies Baxdrostat Study Lanifibranor Trials Eli Lilly Trials TROPION-Breast01 Trial FLAURA2 Trial Durvalumab Treatment Gefurulimab Baxdrostat Trial Results NRG Oncology Trials REMIX Trials BART Trial PROTOSTAR Study IMforte Trial Lecanemab Studies TROPION-Breast02 CROWN Trial OLYMPIA Trials AMPLITUDE Trial ASC4FIRST Trial BOOG 2013-08 Trial Survival Rates Oropharyngeal Cancer lidERA Trial Giredestrant Epioxa Trials DESTINY-Breast Trials REGENCY Study evERA Trial AQUILA Trial LidERA Trial ASCENT-07 Trial DESTINY-Breast09 QUASAR Trial KOMET-001 Study VISIONARY Trial SWIFT Trials inMIND Trial Gout Management Drug Efficacy MDMA Trials MinervaX GBS Vaccine FRESCO-2 Trial Induction Chemotherapy Interlace Trial GALAXI Trials

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

The approval follows late-stage trials showing significant reductions in vomiting versus placebo.

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

Lancet Phase III Trial Finds Proton Therapy Improves 5-Year Survival in Oropharyngeal Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

FDA Approves Koselugo for Adults With NF1-Related Plexiform Neurofibromas

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Kailera Therapeutics Raises $600 Million to Fund Global Phase 3 of Obesity Drug

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy